

Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07)

Catalog # NMI-MY2364



BIOSYSTEMS
Acro

Source

Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) is a rabbit monoclonal antibody recombinantly expressed in HEK293 cells.

Antibody Type

Recombinant Monoclonal

Clone

M1C07

Isotype

Rabbit IgG, Kappa

Immunogen

NMTi-BSA

Specificity

Specifically recognizes NMTi.

Purification

Protein A purified / Protein G purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 µm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.



Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#)
- [Quality Advantages](#)
- [Quality Control Process](#)


Bioactivity-ELISA



Immobilized Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) at 1 µg/mL (100 µL/well) can bind ADC-NMTi with a linear range of 0.5-16 ng/mL (QC tested).

Serial dilutions of NMTi, N-Myristoyltransferase inhibitor were added into Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364): ADC-NMTi binding reactions. The half maximal inhibitory concentration (IC₅₀) is 0.37 µg/mL (Routinely tested).

Cross Verification



ELISA binding of Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) with ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibody respectively.

The coating antibody was Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364), used at 1 µg/mL concentration. The primary antibody were different payload conjugated antibodies, including ADC-NMTi, Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF conjugated antibodies used at 0.5 µg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.

Monoclonal Anti-NMTi Antibody, Rabbit IgG (M1C07) (Cat. No. NMI-MY2364) is specific to ADC-NMTi, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), DM1 Antibody Human IgG and IgG1-MMAF (Routinely tested).

Background

NMTi, a new ADC payload toxin developed by Myricx Bio, inhibits NMT to disrupt mitochondrial function and induce endoplasmic reticulum stress, thereby killing cancer cells. Its simple structure facilitates synthesis. In preclinical studies, it exhibits efficacy and safety in solid tumors; NMTi-ADCs feature dual targeting and strong bystander activity, and outperform T-Dxd in some models.

Discounts, Gifts,
and more!



www.acrobiosystems.com



6/16/2026